WuXi PharmaTech Marks Second Quarter Of Earnings Rebound Following 2008's Devastating Loss
This article was originally published in The Pink Sheet Daily
Executive Summary
The Shanghai-headquartered CRO is moving ahead with plans to invest about $60 million this year into completing the construction of a new drug safety testing center.